Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

20. Oktober 2025 08:00 ET | Quelle: ProQR Therapeutics N.V.

ProQR Receives CTA Authorization for AX-0810 and Announces Virtual Investor and Analyst Event on November 3, 2025

LEIDEN, Netherlands & CAMBRIDGE, Mass., Oct. 20, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA...
13. Oktober 2025 08:30 ET | Quelle: ProQR Therapeutics N.V.

ProQR to Participate in Upcoming Investor Conferences in October 2025

LEIDEN, Netherlands & CAMBRIDGE, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA...
10. Oktober 2025 06:00 ET | Quelle: Shape Therapeutics, Inc.

Shape Therapeutics Shares Breakthrough Preclinical Data for Non-Invasive Treatment of Parkinson’s Disease Using a Brain Targeted AAV Gene Therapy at the European Society of Gene & Cell Therapy 32nd Annual Congress

Preclinical data demonstrates that Shape’s engineered AAV5 variant, SHP-DB1, efficiently targets the NHP brain after intravenous injection and transduces >95% of neurons in the Parkinson's...
26. September 2025 09:00 ET | Quelle: Shape Therapeutics, Inc.

Shape Therapeutics Announces Multiple Oral Presentations at the European Society of Gene & Cell Therapy 32nd Annual Congress

Shape Therapeutics to present at the ESGCT 32nd congress on an RNA-targeting gene therapy for Parkinson's Disease and a novel CNS AAV capsid.
13. März 2025 07:00 ET | Quelle: ProQR Therapeutics N.V.

ProQR Announces Year End 2024 Operating and Financial Results

Axiomer™ ADAR-mediated RNA editing pipeline advancing across liver and CNS programs, with CTA filing on track for Q2 2025 for lead program AX-0810 targeting NTCP for Cholestatic diseases Company...
11. Dezember 2024 07:00 ET | Quelle: ProQR Therapeutics N.V.

ProQR Therapeutics Announces $8.1 Million in New Funding from Rett Syndrome Research Trust to Expand RNA Editing Collaboration

LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 11, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA...
10. Dezember 2024 08:00 ET | Quelle: ProQR Therapeutics N.V.

ProQR Appoints Peter A. Beal, PhD, as Chief ADAR Scientist

LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 10, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA...
07. November 2024 07:00 ET | Quelle: ProQR Therapeutics N.V.

ProQR Announces Third Quarter 2024 Operating and Financial Results

AX-0810 targeting NTCP for cholestatic diseases to be first ProQR Axiomer™ RNA editing program to enter the clinic Company to host virtual Investor and Analyst Event in December to highlight...
07. Oktober 2024 08:00 ET | Quelle: ProQR Therapeutics N.V.

ProQR Highlights Upcoming Presentation at 20th Annual Meeting of the Oligonucleotide Therapeutics Society

LEIDEN, Netherlands & CAMBRIDGE, Mass., Oct. 07, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA...
10. September 2024 16:30 ET | Quelle: ProQR Therapeutics N.V.

ProQR Announces Webcast Presentation at the 2024 Cantor Global Healthcare Conference

LEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. 10, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA...

Nächste Seite